CTRI/2020/02/023327已完成未知
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single oral dose, crossover, bioequivalence study of trimetazidine dihydrochloride extended release capsules 80 mg (Trade Name FLAVEDON OD) OF SERDIA PHARMACEUTICALS PVT. LTD., INDIA comparing with Vastarel® OD 80 MG prolonged release hard capsule (TRADE NAME VASTAREL® OD 80 MG) OF EGIS PHARMACEUTICALS PLC, Hungary, in normal, healthy, adult, human male subjects under fasting condition.
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Non-smokers, normal, healthy, adult, human male volunteers between 18 to 45 years of age (both inclusive).
- •2.Having a Body Mass Index (BMI) ranging within18.5 to 30.0 (both inclusive), calculated as weight in kg / height in m2.
- •3.Not having any significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12-lead ECG and X-ray chest (P/A view) recordings.
- •4.Able to understand and comply with the study procedures, in the opinion of the investigator.
- •5.Able to give voluntary written informed consent for participation in the study.
排除标准
- •1.Known hypersensitivity to Trimetazidine or any excipients or any related drug or any substance.
- •2.History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
- •3.Ingestion of a medication (prescribed & over the counter (OTC) medication including herbal remedies) at any time within 14 days prior to check-in in period-I. In any such case subject selection will be at the discretion of the Principal Investigator / designee.
- •4.Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAIDs induced urticaria.
- •5.Subject having CrCL = 60 ml/min at screening.
- •6.A recent history of harmful use of alcohol (less than 2 years), i.e. alcohol consumption of more than 14 standard drinks per week for men (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40 % distilled spirits, such as rum, whisky, brandy etc.) or consumption of alcohol or alcoholic products within 48 hours prior to check-in of period-I.
- •7.Smokers or who have smoked within last 06 months prior to start of the study.
- •8.The presence of clinically significant abnormal laboratory values during screening.
- •9.Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.
- •10.A history of difficulty with donating blood.
- •11.Difficulty in swallowing solid dosage forms like tablets or capsules.
- •12.Donation of blood (1 unit or 350 mL) within a period of 90 days prior to the first dose of study medication.
- •13. Receipt of an investigational medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication (If investigational medicinal product is received within 90 days where there is no blood loss except safety lab testing, subject can be included considering 10 half-lives duration of investigational medicinal product received)
- •14.A positive hepatitis screen including hepatitis B surface antigen and/or HCV antibodies.
- •15. A positive test result for HIV antibody (I & II).
- •16.Consumption of grape fruit or grape fruit products within 72 hours prior to check-in of period-I.
- •17.An unusual diet, for whatever reason (for example, fasting, high potassium or low-sodium), for four weeks prior to check-in in period-I. In any such case subject selection will be at the discretion of the Principal Investigator.
研究者
相似试验
尚未招募
不适用
Comparative bioavailability study of Test product Alogliptin and Pioglitazone tablets 12.5 mg/45 mg compared with the reference product of Oseni (alogliptin and pioglitazone) tablets 12.5 mg/ 45 mg, in healthy, adult, human subjects, under fed conditions.CTRI/2019/04/018646Indoco Remedies Limited
招募中
不适用
To compare Bioequivalence study of Sitagliptin 100 mg Metformin Hydrochloride 1000 mg extended release Tablets in healthy adult human subjects under fasting conditionsCTRI/2023/02/049858SunGlow Lifescience Private Ltd
进行中（未招募）
Unknown
Bioequivalence study of Esomeprazole 20 mg Naproxen 500 mg Delayed Release Tablets in healthy adult human subjects under fasting conditioCTRI/2023/04/051767Faromed Lifesciences LLP (Subsidiary of Omnicals Pharma Private Limited)
尚未招募
不适用
Comparative bioavailability study of Test product Fesoterodine Fumarate ER Tablets 8 mg compared with the reference product of Toviaz® (fesoterodine fumarate) Extended-Release Tablets 8 mg, in healthy, adult, human subjects, under fed conditions.CTRI/2019/04/018644MSN Laboratories Private Limited
已完成
不适用
A bioequivalence study of Efonidipine 40 mg and Chlorthalidone 12.5 mg tablet combination inhealthy adults.CTRI/2021/03/032140Zuventus Healthcare Limited28